ResMed| (RMD)Director sold ~$520K

~$520K

Approx. value · 2,000 sh @ $260.22

63K

Holds after · shares reported

Traded

Mar 4, 2026

Filed

Mar 6, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jan 2, 2026Insider · 2 peopleInsiders: 2 sales (~$254K)
2. Jan 7, 2026Insider · 2 peopleInsiders: 2 sales (~$1.7M)
3. Jan 29, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
4. Feb 2, 2026InsiderCFO sold ~$257K of RMD shares in the open market
5. Feb 4, 2026Insider · 2 peopleInsiders: 2 sales (~$516K)
6. Feb 9, 2026InsiderCEO sold ~$1.37M of RMD shares in the open market
7. Feb 23, 2026FDAFDA device clearance: Mariana Minerva; Mariana Nimbus
8. Mar 2, 2026InsiderCFO sold ~$254K of RMD shares in the open market
9. Mar 4, 2026 · this disclosureInsiderDirector sold ~$520K of RMD shares in the open market

What came next

1. Mar 9, 2026InsiderCEO sold ~$1.25M of RMD shares in the open market
2. Mar 27, 20265% stakeThe Vanguard Group reported a passive stake (13G)
3. Apr 1, 2026Insider · 2 peopleInsiders: 2 sales (~$674K)
4. Apr 7, 2026InsiderCEO sold ~$1.13M of RMD shares in the open market
5. Apr 8, 2026FDAFDA device clearance: myAir
6. Apr 24, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 30, 2026, ResMed Inc. (the “Company”) announced that Brett Sandercock, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, will retire from his role as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer.”
7. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 8.2%
8. Apr 29, 20265% stakeVanguard Portfolio Management reported a passive stake (13G) of 5.4%
9. Apr 30, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
10. May 7, 2026InsiderCEO sold ~$1.04M of RMD shares in the open market
11. May 27, 2026FDAFDA device clearance: ResScan Essentials
12. Jun 4, 2026FDAFDA device clearance: Orion
13. Jun 8, 2026InsiderCEO sold ~$968K of RMD shares in the open market
14. Jun 25, 2026FDARecall: Resmed Astral 100/150 Resmed Astral 100/50 is a ventilator system that provides continuous or intermittent ventilatory support for patients weighing more than…

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for ResMed|

For ResMed|, OQRO holds 8 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 19 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its RMD page.

Other recent filings by Peter C Farrell, Director

• SEC Form 4 at ResMed| (RMD)Sep 4, 2026
• SEC Form 4 at ResMed| (RMD)Aug 6, 2026
• SEC Form 4 at ResMed| (RMD)Apr 2, 2026
• SEC Form 4 at ResMed| (RMD)Feb 6, 2026
• SEC Form 4 at ResMed| (RMD)Jan 9, 2026

The full history of Peter C Farrell, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at ResMed|

• SEC Form 4Oct 8, 2026
• SEC Form 144Oct 7, 2026
• SEC Form 4Sep 10, 2026
• SEC Form 144Sep 8, 2026
• SEC Form 4Sep 4, 2026
• SEC Form 144Sep 2, 2026

Everything OQRO holds on this company is on its RMD page.